MAVIRET™ 8 week, pan-genotypic HCV treatment, good for CKD & cirrhosis, covered in Ontario

Finally, Maviret, AbbVie's hepatitis C drug, has made it through Canada's approval process and has been listed for coverage by Ontario's PharmaCare. We hope BC PharmaCare will also list it soon. "MAVIRET™ is the first and only 8-week, pan-genotypic treatment for chronic hepatitis C patients without cirrhosis and who are new to treatment (from: Decisions Resources Group. Hepatitis C virus: disease landscape & forecast 2016 and 2017)... MA...